Oral Targeting of Protein Kinase C Receptor: Promising Route for Diabetic Retinopathy?

E-ISSN： 1875-5704|9|4|405-413

ISSN： 1567-2018

Source： Current Drug Delivery, Vol.9, Iss.4, 2012-07, pp. : 405-413

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Protein Kinase C Inhibitors in the Treatment of Diabetic Retinopathy. Review

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-01 ,pp. : 386-391

Bentham Science Publishers

Access to resources Recommend Favorite

The role of Raf-1 kinase in diabetic retinopathy

By Mohammad Ghulam Kowluru Renu A

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 4, 2011-04 ,pp. : 357-364

Informa Healthcare

Access to resources Recommend Favorite

The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications

By Vinik Aaron

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 12, 2005-12 ,pp. : 1547-1559

Informa Healthcare

Access to resources Recommend Favorite

The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 11, 2011-11 ,pp. : 1961-1973

Bentham Science Publishers

Access to resources Recommend Favorite

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies

By Podar Klaus Raab Marc S Chauhan Dharminder Anderson Kenneth C

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 10, 2007-10 ,pp. : 1693-1707

Informa Healthcare

Access to resources Recommend Favorite